Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop
about
Utilization of animal models to investigate non-alcoholic steatohepatitis-associated hepatocellular carcinomaNovel Molecular Mechanisms in the Development of Non-Alcoholic SteatohepatitisNon-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval PathwayClinical assessment of hepatic de novo lipogenesis in non-alcoholic fatty liver diseaseShort-Term Hypocaloric High-Fiber and High-Protein Diet Improves Hepatic Steatosis Assessed by Controlled Attenuation ParameterComparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD): A PRISMA-compliant systematic review and network meta-analysis.Imaging biomarkers for steatohepatitis and fibrosis detection in non-alcoholic fatty liver diseaseNonalcoholic Steatohepatitis and Endpoints in Clinical Trials.Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease.Reduced Lysosomal Acid Lipase Activity in Adult Patients With Non-alcoholic Fatty Liver DiseaseLysosomal Acid Lipase Activity: A Tool for the Detection and Management of Fatty Liver Disease?Association of Circulating Serum miR-34a and miR-122 with Dyslipidemia among Patients with Non-Alcoholic Fatty Liver Disease.Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis.Cardiovascular risk assessment in the treatment of nonalcoholic steatohepatitis: a secondary analysis of the MOZART trial.Clinical guidelines of non-alcoholic fatty liver disease: A systematic review.Review article: novel methods for the treatment of non-alcoholic steatohepatitis - targeting the gut immune system to decrease the systemic inflammatory response without immune suppression.Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis.Surrogate endpoints for clinical trials in primary sclerosing cholangitis: Review and results from an International PSC Study Group consensus process.Natural antioxidants for non-alcoholic fatty liver disease: molecular targets and clinical perspectives.The future of diagnosing NASH - could a simple blood test be the key?Anti-steatotic and anti-fibrotic effects of the KCa3.1 channel inhibitor, Senicapoc, in non-alcoholic liver disease.Fibrosis assessment: impact on current management of chronic liver disease and application of quantitative invasive tools.Histological Assessment of NAFLD.Current and future pharmacologic treatment of nonalcoholic steatohepatitis.Noninvasive diagnosis of nonalcoholic fatty liver disease: Are we there yet?Therapies in non-alcoholic steatohepatitis (NASH).Treatment of nonalcoholic fatty liver disease: Where do we stand? an overview.Novel Pharmacotherapy Options for NASH.Development and validation of a noninvasive prediction model for nonalcoholic steatohepatitis resolution after lifestyle intervention.The therapeutic landscape of non-alcoholic steatohepatitis.Systematic review: Current evidence in non-alcoholic fatty liver disease lacks relevance to patients with advanced fibrosis.Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters.Lipid droplets and liver disease: from basic biology to clinical implications.Dual-photon microscopy-based quantitation of fibrosis-related parameters (q-FP) to model disease progression in steatohepatitis.Assessment of treatment response in non-alcoholic steatohepatitis using advanced magnetic resonance imaging.The prognostic value of hepatic venous pressure gradient in patients with cirrhosis is highly dependent on the accuracy of the technique.Antibody-Directed Glucocorticoid Targeting to CD163 in M2-type Macrophages Attenuates Fructose-Induced Liver Inflammatory Changes.Human hepatic gene expression signature of non-alcoholic fatty liver disease progression, a meta-analysis.Elevated hepatic DPP4 activity promotes insulin resistance and non-alcoholic fatty liver disease.Baseline Parameters in Clinical Trials for Nonalcoholic Steatohepatitis: Recommendations From the Liver Forum.
P2860
Q26748807-EA0C6755-742E-486D-8B15-1619745898E9Q26766533-957C377D-99C9-4CF4-BDF6-FEA93FBA4BEDQ26800894-11F50D49-D0D6-4CD3-B0E9-6BC136329A4DQ28072381-DA55D34F-E30E-49B5-8C48-CC9E91E9376DQ28831365-48516FC3-51E4-4918-AD2A-7378EE7E8D80Q30248535-0E695D3C-AFFA-4FD5-A8C6-8DC01CEC526EQ30376231-1CBDAA27-D2A6-4195-A30B-AF98487355B9Q30396916-E4B84A89-2637-4043-B4C2-F7E8843A882EQ34540703-0F991BFF-78D3-4CB1-B22A-24082CFAA829Q35947534-B163D880-2AC5-4653-A63A-27C96DC9DD34Q35947574-97E5CEFC-D7F2-4D52-94E8-858F3FBA2843Q35989613-082BBE18-0348-4ECC-A8F4-9005C14FC31BQ36291761-38B4FB88-8E1E-4BE7-A2AE-4C1FB0147274Q36569181-305CA06D-A9F8-40A2-B2D1-479C2AF4B851Q37284519-5C694263-66B1-4737-9C40-AB7B6C7A7041Q37563673-F936D9D3-2259-4F88-A529-692D0DD9396AQ38550285-513647FB-72F4-4EDF-81DB-171656D108A1Q38595151-921EC438-0798-44E8-B5DB-1AF9ABF276F5Q38599131-0E041A26-E18D-41AC-9FB6-A3805442163CQ38634380-02DD8180-0FCD-4FAA-8F5A-453F0C57A8ECQ38685245-D11FB4CF-7D60-4AA4-87CE-013658055A3BQ38689700-E2D29A41-9904-44B7-8FE7-7D0FD0C80267Q38732493-2616F538-7E2B-43C1-8D93-5448A4AF6D60Q38739205-643BFA70-50DC-4AF3-93D7-17EB37BC84B6Q38772737-6B3E941A-D005-4318-BC1D-0BC36506E0F5Q38774861-E535616C-BAFA-4B5A-BFF8-0E3CE859B5EFQ38782562-0F944352-A276-47BD-B716-44D3EFF5FF85Q38784790-1F27519A-6D8E-42C1-93B0-29159CAFDF56Q38911612-C4CDA55D-4607-4785-B78A-5D8A18C53539Q38978011-42C4AA7F-EEDE-4D35-B5E5-5913DCDCA4F2Q38994562-24FA707A-1D53-416A-A79B-8F3D02F860F7Q39183375-38C5A668-56A9-40D0-98C0-AE3FA27EB2F2Q39253589-2756A245-B7D8-487A-96B0-9B5E5EF0D72CQ40354046-F5AE4906-3821-4450-B23D-30C3B38A6C2EQ40367115-E684A796-B9B5-4F41-BB3F-B4A0E596E22EQ40665105-E5849D3E-1FE6-48D9-AD08-EDDB0AD4EF5BQ42284206-BFFFF67E-C62F-48B0-AA85-56C2A0546074Q42365504-D08FEE66-4A22-4029-B040-8B5822B7A040Q42377919-77B9FFD0-65FF-4C10-9376-AECA72E7F1F4Q45064430-3CD914C6-8B51-46EB-94D4-0F1F7C4AB70C
P2860
Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Challenges and opportunities i ...... Administration Joint Workshop
@en
type
label
Challenges and opportunities i ...... Administration Joint Workshop
@en
prefLabel
Challenges and opportunities i ...... Administration Joint Workshop
@en
P2093
P2860
P921
P356
P1433
P1476
Challenges and opportunities i ...... Administration Joint Workshop
@en
P2093
American Association for the Study of Liver Diseases
Arthur J McCullough
Arun J Sanyal
Lara Dimick-Santos
Scott L Friedman
United States Food and Drug Administration
P2860
P304
P356
10.1002/HEP.27678
P407
P577
2015-03-19T00:00:00Z